… 56 of them having received adjuvant erlotinib. The reported 2-… percentage of patients with
stage II and III disease in the treated … During the conduct of our study, two phase III trials were …

9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC augments
anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) evaluated …

… In the overall population of the phase III SATURN study of erlotinib maintenance therapy,
erlotinib significantly improved PFS and OS compared with placebo (HR = 0.71 and 0.81, …

… activity in prior early phase studies in patients with EGFR-mutated lung cancer with disease
… was not superior to a first-generation tyrosine kinase inhibitor in the current phase III study. …

… chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients
with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in …

… -label trial of abemaciclib versus erlotinib in patients with stage IV NSCLC and a detectable
… patients (3:2) received either 200 mg abemaciclib twice daily or 150 mg erlotinib once daily …

… erlotinib as third-line compared with those who received erlotinib as second-line [13, 14].
Thus, … as a third- or fourth-line therapy for wild-type EGFR NSCLC for a future phase III study. …

… In this phase III clinical study, we assessed the clinical outcomes of combining erlotinib
with … as second-line chemotherapy for patients with non-small-cell lung cancer (NSCLC). …

… (BETA) phase III trial, bevacizumab was added to erlotinib in patients with relapsed NSCLC.
Although PFS was improved with the combination compared with erlotinib alone (HR, 0.62; …

… In summary, the use of bevacizumab and erlotinib is not recommended in the setting of
combined-modality therapy in stage III NSCLC. This recommendation is based on the lack of an …